FDA Approves New Fast-Acting Insulin, Fiasp, for Diabetes in Adults

The US FDA has approved ultrafast-acting mealtime insulin, Fiasp, designed to be taken just before or within 20 minutes of a meal.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply